Table 2 Progression-free survival Cox regression hazard ratios.

From: Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors

Model

Covariate

Hazard ratio (95% CI)

p

Number of mutations

Number of mutations

0.99 (0.77, 1.28)

0.97

Smoking status

Smoking status (never versus former)

0.46 (0.18, 1.15)

0.1

ECOG performance score

ECOG performance status (per one increment in grade)

3.56 (1.64, 7.73)

< 0.005

Radiomic phenotype

Radiomic phenotype (2 versus 1)

2.66 (1.07, 6.64)

0.04

All covariates except radiomic phenotype

Number of mutations

0.86 (0.65, 1.15)

0.32

Smoking status (never versus former)

0.47 (0.17, 1.31)

0.15

ECOG performance status (per one increment in grade)

3.47 (1.56, 7.72)

< 0.005

All covariates

Radiomic phenotype (2 versus 1)

3.8 (1.35, 10.69)

0.01

Number of mutations

0.91 (0.67, 1.23)

0.53

Smoking status (never versus former)

0.75 (0.26, 2.14)

0.59

ECOG performance status (per one increment in grade)

5.14 (1.99, 13.3)

< 0.005